<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Right-sided native valve infective endocarditis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Right-sided native valve infective endocarditis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Right-sided native valve infective endocarditis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vivian H Chu, MD, MHS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Asher J Schranz, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ann Bolger, MD, FACC, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Sexton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Right-sided native valve infective endocarditis (IE) refers to IE involving the tricuspid or pulmonic valve; isolated right-sided IE accounts for approximately 10 percent of all IE cases; concomitant left-sided and right-sided IE account for approximately 13 percent of all IE cases [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Risk factors for right-sided IE include injection drug use, presence of a cardiac implantable electronic device (CIED) or other intravascular device, and presence of an underlying right-sided cardiac anomaly. Issues related to right-sided IE among people who inject drugs and patients with an intravascular device will be reviewed here.
        </p>
        <p>
         Issues related to right-sided IE among patients with CIEDs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116021.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         Issues related to right-sided IE in the setting of congenital heart disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">
          "Infective endocarditis in children", section on 'Congenital heart disease'
         </a>
         .)
        </p>
        <p>
         Other issues related to IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">
          "Overview of management of infective endocarditis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">
          "Complications and outcome of infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for right-sided IE include [
         <a href="#rid1">
          1,3-5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Injection drug use (IDU).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of a cardiac implantable electronic device (CIED) – In such patients, development of right-sided IE usually reflects infection that has spread beyond the pocket, extending up to the insertion leads. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'CIED systemic infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of an intravascular device such as central line, intra-aortic balloon pump, or ventricular assist device. (See
         <a class="medical medical_review" href="/z/d/html/3806.html" rel="external">
          "Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87834.html" rel="external">
          "Management of long-term mechanical circulatory support devices", section on 'Infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of an underlying right-sided cardiac anomaly. (See
         <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">
          "Infective endocarditis in children", section on 'Congenital heart disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Approximately 90 percent of patients with right-sided IE are people who inject drugs (PWID); in contrast, PWID comprise approximately 20 percent of cases of left-sided IE [
         <a href="#rid6">
          6
         </a>
         ]. Patients with a CIED or other intravascular device account for approximately 9 percent of patients with right-sided IE; patients with an underlying right-sided cardiac anomaly account for approximately 1 percent of patients with right-sided IE [
         <a href="#rid7">
          7,8
         </a>
         ]. Patients may present with isolated right-sided IE (approximately 10 percent of all IE cases) or concomitant left-sided and right-sided IE (approximately 13 percent of all IE cases) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Among PWID, the incidence of right-sided IE is 2 to 4 cases per 1000 years of IDU [
         <a href="#rid1">
          1,9
         </a>
         ]. Historically, IE among PWID has been more common in males (ratio 3:1) [
         <a href="#rid10">
          10
         </a>
         ]; however, the rate among females in the United States is rising [
         <a href="#rid11">
          11,12
         </a>
         ]. Among more than 1600 patients with IE undergoing valve surgery in North Carolina between 2007 and 2017, IE associated with injection drug use was more common among patients who were younger (median age 33 versus 56 years), White (89 versus 63 percent), and female (47 versus 33 percent) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         As use of heroin in the United States nearly doubled between 2002 and 2013 [
         <a href="#rid13">
          13
         </a>
         ], the rate of right-sided IE in PWID increased concomitantly, from 6 to 8 percent of hospitalizations (between 2000 and 2008) to 12 percent (in 2013) [
         <a href="#rid11">
          11
         </a>
         ]. Over this interval, right-sided IE among PWID trended toward younger patients, White persons, and a more similar distribution of males versus females [
         <a href="#rid11">
          11
         </a>
         ]. In a retrospective study of IE hospitalizations in the United States, IE in PWID increased from 15 to 29 percent of IE cases between 2010 and 2015 [
         <a href="#rid14">
          14
         </a>
         ]. Similarly, in one report of hospitalizations for endocarditis in North Carolina between 2010 and 2015, the number of cases increased 12-fold, from 0.2 to 2.7 per 100,000 persons per year [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Steep rises in hospitalizations for IDU-associated IE have been seen in numerous states over the past decade [
         <a href="#rid16">
          16,17
         </a>
         ]. Hospitalizations for IE among PWID increased approximately 12-fold between 2007 and 2017 in North Carolina, from 0.92 to 10.95 per 100,000 [
         <a href="#rid12">
          12
         </a>
         ]. There were more than 2600 hospitalizations, with a steady increase in rates of surgery for IE among this group; in the final year of the study, 42 percent of valve surgeries for IE were performed in PWID. As of 2018, in some regions of the country, PWID comprised 58 percent of all surgeries for IE [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         IE is more common in HIV-infected PWID than in HIV-uninfected PWID [
         <a href="#rid19">
          19-21
         </a>
         ]. One case-control study among PWID in Baltimore noted a fourfold higher incidence of IE in HIV-infected PWID (13.8 versus 3.3 cases per 1000 person-years) [
         <a href="#rid21">
          21
         </a>
         ]. Lower CD4 counts were associated with a higher risk of IE in PWID, even after controlling for frequency of drug injection.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H2917727759">
         <span class="h2">
          Valve involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Right-sided IE accounts for approximately 10 percent of all IE cases [
         <a href="#rid1">
          1
         </a>
         ]. Among patients with right-sided IE, the tricuspid valve is involved in approximately 90 percent of cases; the remainder are usually attributable to pulmonic valve involvement [
         <a href="#rid1">
          1
         </a>
         ]. Rarely, involvement of the Eustachian valve, interventricular septum, and right ventricular free wall have been described [
         <a href="#rid22">
          22,23
         </a>
         ]. Concomitant left-sided and right-sided IE account for approximately 13 percent of all IE cases [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1358232384">
         <span class="h2">
          Mechanism of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among people who inject drugs (PWID), the pathogenesis of right-sided IE may include the following factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Injection of particulate matter (such as talc) along with illicit drugs may cause endothelial damage to the tricuspid valve [
         <a href="#rid10">
          10,24
         </a>
         ]. Particulate matter up to 8 to 10 microns in size may cross pulmonary capillaries and, in turn, abrade or damage the endothelium of the mitral or aortic valves [
         <a href="#rid25">
          25
         </a>
         ]. It is unknown whether this valve damage confers increased IE risk in individuals who discontinue injection drug use (IDU).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repetitive IDU may produce cumulative subclinical damage to the tricuspid valve. In one study of asymptomatic patients with a history of heroin use but no history of IE, tricuspid valve abnormalities were observed on transthoracic echocardiography [
         <a href="#rid26">
          26
         </a>
         ]. However, others have not observed an increase in gross valvular abnormalities in PWID who died of causes other than IE [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the process of IDU, patients may also inject bacteria or fungi present on the surface of the skin, in the drug itself, or in diluents, fillers, or filters used to prepare drugs for injection [
         <a href="#rid24">
          24
         </a>
         ]. Illicit drugs in contaminated syringes may contain up to 10
         <sup>
          8
         </sup>
         organisms/mL [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PWID have higher rates of nasal and cutaneous colonization with
         <em>
          Staphylococcus aureus
         </em>
         than patients who use illicit drugs by the oral route exclusively [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cocaine injection may carry an extra risk of IE due to associated vasospasm, which can result in skin or other tissue damage [
         <a href="#rid28">
          28
         </a>
         ]. In one study of 115 hospitalizations for PWID with history of cocaine use, IE was diagnosed in 20 percent of cases; a history of cocaine use was more common in those with IE than in those without [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of saliva as a drug diluent and/or on injection equipment increases risk for infection from oropharyngeal flora, including
         <em>
          Haemophilus parainfluenzae
         </em>
         ,
         <em>
          Eikenella corrodens
         </em>
         , and
         <em>
          Streptococcus milleri
         </em>
         .
        </p>
        <p>
        </p>
        <p>
         Among patients with cardiac implantable electronic devices and other intravascular devices, the pathogenesis of right-sided IE begins with bacterial contamination at the time of implantation or subsequent handling.
        </p>
        <p>
         The pathogenesis of vegetation formation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2140.html" rel="external">
          "Pathogenesis of vegetation formation in infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          S. aureus
         </em>
         is the most common cause of right-sided IE, accounting for up to 70 percent of cases [
         <a href="#rid25">
          25,30-34
         </a>
         ]. Streptococci and enterococci are the next most common pathogens, accounting for 5 to 30 percent and 2 to 5 percent of cases, respectively.
        </p>
        <p>
         Historically, fungi and gram-negative bacilli were rare causes of right-sided IE [
         <a href="#rid24">
          24,30,35-37
         </a>
         ], and polymicrobial IE had been reported in a small percentage of cases of right-sided IE [
         <a href="#rid32">
          32,38
         </a>
         ]. However, the microbiology of right-sided IE is changing as PWID comprise a larger proportion of patients.
        </p>
        <p>
         One large study of IE among PWID found that
         <em>
          S.
         </em>
         <em>
          aureus
         </em>
         was implicated in only 50 percent of cases [
         <a href="#rid39">
          39
         </a>
         ]. Gram-negative rods were reported in up to 5 percent of cases (most commonly
         <em>
          Pseudomonas
         </em>
         spp and
         <em>
          Serratia
         </em>
         spp);
         <em>
          Candida
         </em>
         spp were reported in 5 percent.
        </p>
        <p>
         Culture-negative right-sided IE among patients with cardiac devices has been described [
         <a href="#rid1">
          1,40,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Microbiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3849185484">
         <span class="h2">
          Signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may present with isolated right-sided IE (approximately 10 percent of all IE cases), or concomitant left-sided and right-sided IE (approximately 13 percent of all IE cases) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         Fever is the most common symptom of right-sided IE (up to 90 percent of patients); it is often associated with chills, anorexia, and weight loss [
         <a href="#rid42">
          42
         </a>
         ]. Fever patterns in IE vary widely; their temporal patterns or severity have no diagnostic utility. Other common symptoms include malaise, headache, myalgias, arthralgias, night sweats, abdominal pain, and dyspnea.
        </p>
        <p>
         Septic pulmonary emboli are common among patients with right-sided IE, occurring in up to 53 percent of patients with tricuspid involvement; clinical manifestations of such emboli include cough, pleuritic chest pain, hemoptysis, and dyspnea [
         <a href="#rid42">
          42
         </a>
         ]. Right-sided IE of the tricuspid valve may also present with pulmonary symptoms mimicking a respiratory tract infection. Other manifestations include anemia and microscopic hematuria (possibly due to immune complex deposition rather than systemic emboli) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         In the setting of delayed diagnosis, complications may include pulmonary infarcts, pulmonary abscesses, pleural effusion, empyema, and, rarely, pneumothorax [
         <a href="#rid1">
          1,2,43
         </a>
         ]. These may be associated with right heart failure and right atrial dilatation with associated supraventricular arrhythmia [
         <a href="#rid2">
          2
         </a>
         ]. In addition, mycotic aneurysm of the pulmonary artery can occur; rupture can lead to hemoptysis [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4337.html" rel="external">
          "Overview of pulmonary disease in people who inject drugs"
         </a>
         .)
        </p>
        <p>
         Patients with isolated right-sided IE often do not have a detectable heart murmur (in contrast to patients with left-sided IE), and left-sided heart failure is unusual [
         <a href="#rid24">
          24
         </a>
         ]. While manifestations of peripheral embolization are observed less frequently in patients with isolated right-sided IE, metastatic infection associated with
         <em>
          S. aureus
         </em>
         bacteremia in the setting of right-sided IE is possible
         <em>
          .
         </em>
         This is due to the propensity for bloodstream infections due to
         <em>
          S. aureus
         </em>
         to cause disseminated infection, which may occur with or without concurrent endocarditis. Rarely, patients with right-sided IE can develop systemic emboli via an atrial septal abnormality, especially in the setting of concurrent pulmonary hypertension. (See
         <a class="medical medical_review" href="/z/d/html/1092.html" rel="external">
          "Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults", section on 'Paradoxical emboli'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2966222018">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of suspected IE, the physical examination should include assessment for evidence of right- and left-sided involvement. This includes cardiac examination (for signs of new regurgitant murmurs or heart failure), chest examination (for crackles, consolidation, or diminished breath sounds), and evaluation for evidence of septic emboli with special attention to the fundi, conjunctivae, skin, and digits. The physical examination should also include evaluation for bone or joint abnormalities (particularly focal back discomfort, suggesting vertebral osteomyelitis, discitis, and/or epidural abscess), abdominal pain (particularly left upper quadrant pain, which may reflect splenic infarction), and costovertebral angle tenderness (which may reflect renal infarction or psoas abscess). In addition, a neurologic examination should be undertaken to evaluate for evidence of focal neurologic impairment. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'History and physical examination'
         </a>
         .)
        </p>
        <p>
         Serial bedside examinations are critical for detection of complications that may develop after initial evaluation and during the course of treatment.
        </p>
        <p class="headingAnchor" id="H3406083149">
         <span class="h2">
          Chest radiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with right-sided IE, chest radiography demonstrates septic pulmonary emboli (single or multiple pulmonary infiltrates with central cavitation) in more than half of cases  (
         <a class="graphic graphic_diagnosticimage graphicRef59037" href="/z/d/graphic/59037.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid45">
          45
         </a>
         ]. These lesions typically measure 5 to 35 mm and favor basilar and peripheral lung locations, and they may increase in number from one day to the next. The extent of septic pulmonary emboli may be better delineated on computed tomography than chest radiography.
        </p>
        <p>
         Other findings on chest radiography may include pulmonary abscesses, pleural effusion, and pneumothorax.
        </p>
        <p class="headingAnchor" id="H2081402729">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory findings in the setting of IE are relatively nonspecific; they are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Laboratory and ECG findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H407269316">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3532524653">
         <span class="h2">
          Criteria for diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of right-sided IE should be suspected in patients with fever, with or without respiratory symptoms (such as cough, chest pain, hemoptysis), in the setting of relevant risk factors (injection drug use [IDU], presence of an intravascular device).
        </p>
        <p>
         The diagnosis of right-sided IE is established based on clinical manifestations, blood cultures (or other microbiologic data), and echocardiography; additional diagnostic evaluation for patients with suspected or known IE includes electrocardiography, chest radiography, and other radiographic imaging (tailored to clinical manifestations):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A definitive diagnosis of right-sided IE may be established in the setting of positive blood cultures in combination with echocardiographic evidence of right-sided vegetation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A presumptive diagnosis of right-sided IE may be made in the setting of suggestive clinical history, physical examination findings, and laboratory data in the setting of relevant risk factor(s). As an example, a presumptive diagnosis of right-sided IE may be made for people who inject drugs (PWID) with pulmonary manifestations and positive blood cultures for
         <em>
          S. aureus
         </em>
         , even in the setting of negative echocardiography.
        </p>
        <p>
        </p>
        <p>
         Patients with right-sided IE may fulfill the 2023 Duke-International Society for Cardiovascular Infectious Disease (ISCVID) criteria [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on '2023 Duke-ISCVID criteria'
         </a>
         .)
        </p>
        <p>
         However, these criteria were developed for evaluation of patients with left-sided IE, and their sensitivity is diminished in patients with suspected right-sided IE and cardiac device infection [
         <a href="#rid47">
          47
         </a>
         ]. This is because patients with right-sided IE may not have an audible murmur, peripheral emboli, or immunologic and/or vascular phenomena. However, important clues for right-sided IE that are included in the modified Duke minor criteria include IDU and presence of septic pulmonary emboli.
        </p>
        <p class="headingAnchor" id="H107934560">
         <span class="h2">
          Diagnostic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation for patients with suspected IE consists of blood cultures and echocardiography:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least three sets of blood cultures should be obtained from separate venipuncture sites (ideally spaced over 30 to 60 minutes) prior to initiation of antibiotic therapy. (See
         <a class="medical medical_review" href="/z/d/html/2133.html" rel="external">
          "Detection of bacteremia: Blood cultures and other diagnostic tests"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following collection of blood cultures, the decision to start or withhold antibiotic therapy prior to a microbiologic diagnosis must be individualized. (See
         <a class="local">
          'Empiric antibiotic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Echocardiography should be performed in all patients with suspected IE, particularly for patients with positive blood cultures and/or evidence of septic pulmonary emboli  (
         <a class="graphic graphic_algorithm graphicRef106519" href="/z/d/graphic/106519.html" rel="external">
          algorithm 1
         </a>
         ). In general, transthoracic echocardiography (TTE) is the first diagnostic test for patients with suspected IE. Transesophageal echocardiography (TEE) has higher sensitivity than TTE (particularly in the setting of concomitant left-sided disease), and is better for detection of cardiac complications such as abscess, leaflet perforation, and pseudoaneurysm. In some circumstances, it is reasonable to forgo TTE and proceed to TEE. (See
         <a class="local">
          'Echocardiography'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Additional diagnostic evaluation for patients with suspected or known right-sided IE includes electrocardiography, chest radiography, and additional radiographic imaging tailored to clinical manifestations.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrocardiography (ECG)
         </strong>
         – Baseline ECG should be performed as part of the initial evaluation for all patients with suspected IE, with subsequent telemetry monitoring or serial electrocardiograms. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2115.html" rel="external">
          "ECG tutorial: Basic principles of ECG analysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The presence of heart block or conduction delay (which may manifest initially as a prolonged PR interval) may provide an important clue to paravalvular extension of infection to the valve annulus and adjacent septum. In addition, the presence of findings consistent with ischemia or infarction may suggest the presence of emboli to the coronary circulation. These complications may be observed in patients with left-sided or bilateral IE, but generally do not occur in the setting of isolated right-sided IE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest radiography
         </strong>
         – Chest radiography is warranted to evaluate for presence of septic pulmonary emboli, infiltrate (with or without cavitation), congestive heart failure, lung abscess, and potential alternative causes of fever and systemic symptoms. (See
         <a class="local">
          'Chest radiography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Computed tomography (CT)
         </strong>
         – In patients with persistent fever and/or physical findings suggestive of focal infection, CT of the torso (chest, abdomen, and pelvis) is useful to evaluate for subclinical sites of metastatic infection (such as splenic infarct, renal infarcts, psoas abscess, or other sites of infection) that may warrant localized drainage [
         <a href="#rid48">
          48,49
         </a>
         ]. Routine brain or spine imaging with CT or magnetic resonance imaging (MRI) is not necessary in the absence of focal neurologic signs or symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional radiographic imaging
         </strong>
         to evaluate for complications of IE should be tailored to findings on history and physical examination [
         <a href="#rid48">
          48
         </a>
         ]. As examples, patients with back pain should be evaluated for vertebral osteomyelitis or epidural abscess with MRI, and patients with headache, neurologic deficits, or meningeal signs should be evaluated with head MRI for neurologic complications (including intracranial mycotic aneurysm or central nervous system bleeding). (See
         <a class="medical medical_review" href="/z/d/html/2129.html" rel="external">
          "Overview of infected (mycotic) arterial aneurysm"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients who undergo valve replacement, the valve should be sent for culture and histopathology. (See
         <a class="local">
          'Microbiology cultures'
         </a>
         below.)
        </p>
        <p>
         General issues related to diagnosis of left-sided native valve endocarditis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2029141843">
         <span class="h2">
          Diagnostic tools
         </span>
        </p>
        <p class="headingAnchor" id="H2453502845">
         <span class="h3">
          Microbiology cultures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Microbiologic tools for diagnosis of IE include blood cultures and valve culture. The results of a valve tissue gram stain may be useful in guiding antimicrobial therapy if it yields an unexpected finding (eg, a gram-negative rod on valve tissue in a patient whose blood cultures had thus far grown only
         <em>
          S. aureus
         </em>
         )
         <em>
          .
         </em>
         The sensitivity and specificity of these tools for diagnosis of IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         Some centers perform routine molecular analysis of explanted valve tissue, sequencing ribosomal ribonucleic acid (rRNA) to identify microorganisms, which may provide additional diagnostic information [
         <a href="#rid50">
          50
         </a>
         ]. Clinicians should be careful to distinguish these results from cultures, the latter of which assess for viable organisms. Unexpected results from molecular analysis should be interpreted on a case-by-case basis.
        </p>
        <p class="headingAnchor" id="H4014168623">
         <span class="h3">
          Cardiac imaging
         </span>
        </p>
        <p class="headingAnchor" id="H928621539">
         <span class="h4">
          Echocardiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among PWID, the sensitivity of TTE may be comparable with TEE for diagnosis of right-sided IE [
         <a href="#rid51">
          51-53
         </a>
         ]. Given that PWID are at risk for left-sided as well as right-sided IE, the approach to echocardiography for diagnosis of right-sided IE is the same as the approach for diagnosis of left-sided IE  (
         <a class="graphic graphic_algorithm graphicRef106519" href="/z/d/graphic/106519.html" rel="external">
          algorithm 1
         </a>
         ); this is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults"
         </a>
         .)
        </p>
        <p>
         Issues related to echocardiography for diagnosis of IE associated with cardiac devices are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H197589879">
         <span class="h4">
          Other imaging tools
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional cardiac imaging tools for diagnosis of IE include cardiac MRI, cardiac CT, cardiac CT angiography (CTA), and fluorodeoxyglucose positron emission tomography with CT or CTA.
        </p>
        <p>
         Issues related to these tools for diagnosis of IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3896363969">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of bacteremia in the absence of evidence for valvular vegetation includes alternative causes of bacteremia (which may coexist with IE); these are summarized separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         The differential diagnosis for febrile illness accompanied by pulmonary symptoms includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pneumonia
         </strong>
         – Pneumonia refers to infection of the lower respiratory tract; the diagnosis requires demonstration of an infiltrate on chest imaging in a patient with a clinically compatible syndrome (eg, fever, dyspnea, cough, and leukocytosis). (See
         <a class="medical medical_review" href="/z/d/html/4337.html" rel="external">
          "Overview of pulmonary disease in people who inject drugs", section on 'Pneumonia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117561.html" rel="external">
          "Overview of community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary embolism/infarction
         </strong>
         – Pulmonary embolism refers to obstruction of a pulmonary artery or one of its branches by thrombus or other material that originated elsewhere in the body. Symptoms may include dyspnea, chest pain, and cough. The diagnosis is usually established via computed tomographic pulmonary angiography. (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypersensitivity pneumonitis
         </strong>
         – Hypersensitivity pneumonitis refers to lung inflammation due to inhaled dust, fungi, or chemicals. Clinical manifestations include fever, chills, malaise, cough, chest tightness, and dyspnea. The diagnostic approach may include radiographic imaging, laboratory testing, bronchoscopy, and lung biopsy. (See
         <a class="medical medical_review" href="/z/d/html/4337.html" rel="external">
          "Overview of pulmonary disease in people who inject drugs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, successful management of right-sided IE requires parenteral antimicrobial therapy and removal of any indwelling intravascular devices, if present; the approach to antibiotic selection is discussed below. In addition, surgical consultation is warranted in all patients with IE; indications for surgery are discussed below.
        </p>
        <p class="headingAnchor" id="H462166666">
         <span class="h2">
          Empiric antibiotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following collection of blood cultures, the decision to start or withhold antibiotic therapy prior to a microbiologic diagnosis must be individualized. For patients with hemodynamic instability and clinical presentation suggestive of IE, we suggest administration of empiric antibiotic therapy once blood cultures have been obtained. For patients who are clinically stable, antimicrobial therapy may be deferred while awaiting the results of blood cultures and other diagnostic tests.
        </p>
        <p>
         Issues related to selection of empiric therapy for patients with suspected or known right-sided IE are as discussed separately for left-sided IE. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H706766618">
         <span class="h2">
          Surgical assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical consultation is warranted in patients with IE; indications for surgical intervention may develop or progress rapidly.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         - Indications for surgery in right-sided IE include [
         <a href="#rid48">
          48,54
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Very large vegetation (≥20 mm)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent septic pulmonary emboli
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of a highly resistant organism
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent bacteremia despite appropriate antimicrobial therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Less common indications for surgery in right-sided IE include [
         <a href="#rid48">
          48,55
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Right heart failure due to severe tricuspid regurgitation (poorly responsive to medical management) - In general, tricuspid regurgitation is better tolerated (from a hemodynamic standpoint) than mitral regurgitation; therefore, heart failure is a less common indication for surgery in patients isolated tricuspid valve endocarditis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heart block
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Paravalvular abscess
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical approach
         </strong>
         – Surgical approaches for tricuspid valve surgery include repair or replacement. In general, valve repair is preferred over valve replacement; the approach depends on the extent of valvular damage and local expertise [
         <a href="#rid48">
          48
         </a>
         ]. In a systematic review and meta-analysis including 12 retrospective studies including more than 1000 patients who underwent valve repair or valve replacement for management of tricuspid valve endocarditis, no difference in mortality was observed [
         <a href="#rid56">
          56
         </a>
         ]. Valve repair was associated with lower risk for recurrent IE (relative risk 0.17, 95% CI 0.05 to 0.57), need for reoperation (relative risk 0.26, 95% CI 0.07 to 0.92), and need for permanent pacemaker placement (relative risk 0.20, 95% CI 0.11 to 0.35)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3026505464">
         <span class="h2">
          Monitoring response to initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with
         <em>
          S. aureus
         </em>
         endocarditis may remain febrile for five to seven days after initiation of therapy. Patients with right-sided IE and septic pulmonary emboli may remain febrile for an even longer duration of time.
        </p>
        <p>
         The initial microbiologic response to therapy should be assessed by obtaining repeat blood cultures 48 hours after antibiotics are begun; it is reasonable to obtain at least two sets of blood cultures every 24 to 48 hours until bloodstream infection has cleared. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Clinical response to initial therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         Thereafter, careful serial physical examinations should be performed to evaluate for complications. Patients who develop new complications while on appropriate antimicrobial therapy (such as metastatic infection) should have a repeat echocardiogram to assess for worsening valve dysfunction, cardiac abscess, or fistula.
        </p>
        <p class="headingAnchor" id="H3295770723">
         <span class="h2">
          Targeted antibiotic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3335326413">
         <span class="h3">
          Uncomplicated right-sided NVE due to MSSA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with uncomplicated right-sided NVE due to methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA), we favor a two-week regimen of
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         (12 g per 24 hours IV in four or six divided doses) or flucloxacillin (2 g IV every four to six hours) [
         <a href="#rid48">
          48,57
         </a>
         ]. For patients with hypersensitivity to the preceding agents, a two-week regimen of
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         (2 g IV every eight hours) may be given, although this agent is not as well studied for treatment of right-sided IE as the semisynthetic penicillins.
        </p>
        <p>
         Exclusion criteria for the above approach include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of concomitant left-sided endocarditis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of cardiac complications (such as paravalvular abscess, heart block)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extrapulmonary metastatic infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to defervesce and clear blood cultures within 48 to 72 hours of appropriate antibiotic therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal failure
        </p>
        <p>
        </p>
        <p>
         The above approach is supported by a randomized trial including 90 PWID with uncomplicated right-sided MSSA IE treated with
         <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">
          cloxacillin
         </a>
         (with or without
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ); treatment was curative in 89 and 86 percent of patients, respectively [
         <a href="#rid58">
          58
         </a>
         ]. The approach to choice of antibiotic agent for treatment of right-sided IE due to MSSA is also based on data for treatment of MSSA bacteremia and MSSA left-sided IE; this is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Methicillin-sensitive S. aureus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Methicillin susceptible'
         </a>
         .)
        </p>
        <p>
         We are in agreement with the American Heart Association guidelines, which recommend against use of adjunctive aminoglycoside therapy in the two-week beta-lactam regimen for treatment of uncomplicated right-sided IE due to MSSA [
         <a href="#rid48">
          48
         </a>
         ]. While such combination therapy has been shown to be effective in randomized trials [
         <a href="#rid57">
          57,59
         </a>
         ], a growing body of literature suggests use of adjunctive aminoglycoside therapy does not confer additional benefit over beta-lactam monotherapy and may cause harm [
         <a href="#rid57">
          57,58,60,61
         </a>
         ]. Issues related to nephrotoxicity associated with adjunctive aminoglycoside therapy are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'General approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults"
         </a>
         .)
        </p>
        <p>
         For patients with beta-lactam hypersensitivity, alternative agents include treatment with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (or teicoplanin) for four weeks; administration of glycopeptides for two weeks has been associated with high rates of treatment failure [
         <a href="#rid57">
          57,59,60,62
         </a>
         ]. As an example, in a randomized trial including 31 patients with right-sided IE due to
         <em>
          S. aureus
         </em>
         treated with cloxacillin-gentamicin, vancomycin-gentamicin, or teicoplanin-gentamicin, cure rates were 100, 60, and 70 percent, respectively [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         For patients unable to tolerate
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (6 mg/kg intravenously every 24 hours for 4 weeks) is an acceptable alternative agent [
         <a href="#rid48">
          48
         </a>
         ]. Data on use of daptomycin for treatment of right-sided IE are limited. In one randomized trial including 124 patients with
         <em>
          S. aureus
         </em>
         bacteremia (of whom 10 patients had a final diagnosis of uncomplicated right-sided IE) treated with daptomycin monotherapy or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         plus either an antistaphylococcal penicillin or vancomycin for 14 to 28 days, treatment success rates for patients with right-sided IE were 50 versus 25 percent, respectively (absolute difference 25, 95% CI -33 to 83) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Completion of treatment with oral therapy has been evaluated in small case series; further study is needed to guide this approach [
         <a href="#rid64">
          64-66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1469087174">
         <span class="h3">
          Targeted therapy for other patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with complicated right-sided IE due to MSSA (eg, patients with one or more of the above exclusion criteria for treatment of uncomplicated infection), treatment is as for left-sided IE due to MSSA. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Methicillin susceptible'
         </a>
         .)
        </p>
        <p>
         For patients with right-sided IE due to methicillin-resistant
         <em>
          S. aureus
         </em>
         or other pathogens, treatment is as for left-sided IE. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3103136401">
         <span class="h2">
          Completing antibiotic therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         – Once hemodynamically stable, the bacteremia has cleared (as evidenced by negative blood cultures), and a decision on early surgery has been addressed, intravenous therapy may be completed on an outpatient basis. Patients must be capable of managing the technical aspects of intravenous therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A history of recent injection drug use should not automatically exclude candidacy for outpatient parenteral antimicrobial therapy (OPAT). Emerging literature has demonstrated that selected PWID have good outcomes participating in OPAT for IE and comparable invasive infections [
         <a href="#rid67">
          67
         </a>
         ]. Some centers have developed specific criteria to identify PWID who may be eligible for OPAT [
         <a href="#rid68">
          68
         </a>
         ]. Many criteria used in consideration of OPAT among PWID resemble those among the general population of patients evaluated for OPAT (eg, stable housing, social support, transportation to appointments). Decisions about OPAT for all patients should be made on a case-by-case basis and, in the case of PWID, should include input from addiction-treating providers, if available. (See
         <a class="medical medical_review" href="/z/d/html/117307.html" rel="external">
          "Outpatient parenteral antimicrobial therapy", section on 'Patient selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients on OPAT require careful monitoring and must have ready access to full medical care should complications occur [
         <a href="#rid48">
          48,69
         </a>
         ]. Patients should be counseled regarding the need for immediate evaluation in the setting of new fever, chills, or other signs of systemic toxicity, including a thorough clinical evaluation and repeat blood cultures [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117307.html" rel="external">
          "Outpatient parenteral antimicrobial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While on antimicrobial therapy, patients should be monitored for antimicrobial toxicity. Weekly laboratory monitoring (eg, complete blood count, chemistries, liver function tests) should be performed. The specific tests are indicated by the specific antimicrobial regimen  (
         <a class="graphic graphic_table graphicRef121957" href="/z/d/graphic/121957.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are unable to complete parenteral antimicrobial therapy
         </strong>
         – For patients who are unable to complete parenteral antimicrobial therapy (either inpatient or outpatient), completion of treatment with oral therapy is an alternative consideration; however, data to support this approach are very limited [
         <a href="#rid70">
          70
         </a>
         ]. In a retrospective study including more than 100 PWID with complicated
         <em>
          S. aureus
         </em>
         bacteremia who received a partial course of inpatient parenteral therapy, those who were discharged with oral antibiotic therapy had a lower rate of microbiological failure or death than those who did not receive oral antibiotics on discharge (13 versus 44 percent), although there were significant differences in baseline characteristics between the two groups [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal oral antibiotic regimen is uncertain, and data are limited. Some regimens proposed by the AHA 2022 statement on management of endocarditis in PWID are summarized in the table  (
         <a class="graphic graphic_table graphicRef140428" href="/z/d/graphic/140428.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid70">
          70
         </a>
         ]. Patients discharged on oral therapy should be followed closely and be evaluated in the outpatient setting within one week after discharge.
        </p>
        <p>
        </p>
        <p>
         Issues related to echocardiographic monitoring during therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">
          "Overview of management of infective endocarditis in adults", section on 'Echo monitoring during therapy'
         </a>
         .)
        </p>
        <p>
         Patients should be monitored for development of complications related to IE (see
         <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">
          "Complications and outcome of infective endocarditis"
         </a>
         ). Development of complications should prompt evaluation for cardiac surgery.
        </p>
        <p class="headingAnchor" id="H3409553830">
         <span class="h2">
          Follow up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to follow up after completion of antibiotic therapy for IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">
          "Overview of management of infective endocarditis in adults", section on 'Follow-up'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1278909134">
         <span class="h2">
          Additional issues for PWID
         </span>
         <span class="headingEndMark">
          —
         </span>
         People who inject drugs (PWID) may have coinfection with HIV, hepatitis C, or hepatitis B. Accordingly, laboratory testing for these conditions should be pursued, and patients should be immunized against hepatitis A and hepatitis B if needed (see related topics). In addition, PWID with opioid use disorder warrant evaluation, management, and harm reduction interventions; these include provision of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , education on safe injection strategies, and referral to syringe programs and overdose prevention centers, where legal and available (see related topics).
        </p>
        <p class="headingAnchor" id="H857938580">
         <span class="h1">
          REPEAT EPISODES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeat episodes of right-sided IE may occur [
         <a href="#rid72">
          72,73
         </a>
         ]. In general, ongoing injection drug use increases risk of recurrent IE [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         It can be difficult to distinguish whether a repeat episode represents a relapse of the original infection or a new infection. Relapsed infection should be suspected if the repeat episode occurs within six months of the original infection.
        </p>
        <p>
         Bacterial isolates should be retested carefully for complete antibiotic susceptibility profiles. Molecular studies (such as pulsed-field gel electrophoresis) on serial isolates can be used to for definitive distinction, although in general such testing is not routinely available [
         <a href="#rid72">
          72,74
         </a>
         ].
        </p>
        <p>
         Patients with relapse of IE following completion of appropriate antimicrobial therapy should receive a repeat course of antibiotics (tailored to susceptibility results) as described above. In addition, attention should be given to management of relevant risk factors such as injection drug use.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          OUTCOMES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overall prognosis
         </strong>
         − In general, the prognosis for right-sided IE among people who inject drugs (PWID) who do not require surgery is relatively favorable [
         <a href="#rid25">
          25,32,54,58,60,75
         </a>
         ]. In one retrospective study including 220 PWID with right-sided IE, the overall mortality was 6 percent [
         <a href="#rid54">
          54
         </a>
         ]. Factors associated with increased mortality on multivariate analysis included vegetation size &gt;2 cm (odds ratio [OR] 10.2, 95% CI 1.6-78) and fungal etiology (OR 46.2, 95% CI 2.4-1100): mortality 67 versus 3.6 percent with non-fungal etiology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vegetation size
         </strong>
         − Vegetation size has prognostic importance among PWID with right-sided IE. In one series including 51 patients with tricuspid valve IE (most of whom were cured with medical therapy), patients with vegetation &gt;1 cm were more likely to develop congestive heart failure [
         <a href="#rid76">
          76
         </a>
         ]. In another study including 122 patients of tricuspid valve IE, mortality rates in patients with vegetations &lt;1 cm, 1.1 to 2 cm, and &gt;2 cm were 0, 3, and 33 percent, respectively [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         − HIV infection does not appear to be a clear risk factor for poor outcome in IE associated with injection drug use (IDU). In one study including 283 PWID with IE, mortality was not influenced by HIV infection [
         <a href="#rid77">
          77
         </a>
         ]. However, among the 216 HIV-infected patients, survival was lower among the patients with CD4 counts &lt;200/microL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical outcomes and PWID
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial valve surgery
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Short-term outcomes
         </strong>
         − In some studies, worse short-term outcomes have been observed among PWID, including higher rates of postoperative complications such as pneumonia, renal insufficiency, sepsis, and embolism [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In one study including more than 11,000 valve operations for IE, the risk-adjusted short-term mortality was higher among those with IDU (OR 1.51, 95% CI 1.19-1.91) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In contrast, other data suggest better short-term outcomes among PWID with IE (including lower mortality rate during the index admission [
         <a href="#rid14">
          14
         </a>
         ]); this may be attributable to younger age, fewer comorbidities, and more frequent incidence of right-sided IE among PWID and IE [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Long-term
         </strong>
         <strong>
          outcomes
         </strong>
         − Long-term outcomes after surgery for right-sided IE have been observed to be less favorable among PWID than other patients in several studies; frequently, surgery is successful but such patients are often readmitted because of reinfection and complications of ongoing drug use [
         <a href="#rid79">
          79-82
         </a>
         ]. One series of PWID with IE noted a 45 percent mortality (median follow-up period 22 months) [
         <a href="#rid83">
          83
         </a>
         ]; another noted a mortality rate of 33 percent (median follow-up period 3.5 years) [
         <a href="#rid34">
          34
         </a>
         ]. In another study including PWID and IE and patients with IE in the absence of IDU, readmission rates were similar between the groups, but reasons for readmission differed; PWID with IE were more likely to be readmitted for IE, septicemia, and drug abuse than patients with IE in the absence of IDU [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Repeat valve surgery
         </strong>
         − Repeat valve surgery for IE among PWID is associated with increased risk for mortality. In one cohort study including 925 patients, the 30-day mortality among PWID who underwent repeat valve surgery compared with first-time surgery was 8.2 versus 4.8 percent [
         <a href="#rid84">
          84
         </a>
         ]. On multivariable analysis, repeat valve surgery was associated with an increased risk of 30-day mortality (OR 2.22, 95% CI 1.22-4.06). However, there was no direct comparison with outcomes among the general population undergoing valve surgery for IE.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H123743954">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112042.html" rel="external">
          "Society guideline links: Treatment and prevention of infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349562558">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17037.html" rel="external">
          "Patient education: Endocarditis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2389460">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Valve involvement
         </strong>
         – Right-sided native valve infective endocarditis (IE) refers to IE involving the tricuspid or pulmonic valve; isolated right-sided IE accounts for approximately 10 percent of all IE cases; concomitant left-sided and right-sided IE account for approximately 13 percent of all IE cases. Among patients with right-sided IE, the tricuspid valve is involved more frequently than the pulmonic valve. (See
         <a class="local">
          'Valve involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Risk factors for right-sided IE include injection drug use, presence of a cardiac implantable electronic device or other intravascular device, and presence of an underlying right-sided cardiac anomaly. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         – Right-sided IE is attributable to
         <em>
          Staphylococcus aureus
         </em>
         in a majority of cases. Streptococci and enterococci are the next most common pathogens. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Signs and symptoms
         </strong>
         – Right-sided IE commonly presents with fever (up to 90 percent of patients); it is often associated with chills, anorexia, and weight loss. Other common symptoms include malaise, headache, myalgias, arthralgias, night sweats, abdominal pain, and dyspnea. Septic pulmonary emboli occur in up to 75 percent of patients with tricuspid involvement; clinical manifestations include cough, pleuritic chest pain, hemoptysis, and dyspnea. Patients with isolated right-sided IE often do not have a detectable heart murmur (in contrast to patients with left-sided IE), and left-sided heart failure is unusual. (See
         <a class="local">
          'Signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Criteria for diagnosis
         </strong>
         – The diagnosis of right-sided IE should be suspected in patients with fever, with or without respiratory symptoms (such as cough, chest pain, hemoptysis), in the setting of relevant risk factors. A definitive diagnosis of right-sided IE may be established in the setting of positive blood cultures in combination with echocardiographic evidence of right-sided vegetation. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on '2023 Duke-ISCVID criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A presumptive diagnosis of right-sided IE may be made in the setting of suggestive clinical history, physical examination findings, and laboratory data in the setting of relevant risk factors. (See
         <a class="local">
          'Criteria for diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – The diagnostic evaluation for patients with suspected IE includes blood cultures (at least three sets obtained from separate venipuncture sites prior to initiation of antibiotic therapy) and echocardiography  (
         <a class="graphic graphic_algorithm graphicRef106519" href="/z/d/graphic/106519.html" rel="external">
          algorithm 1
         </a>
         ), as well as electrocardiography, chest radiography, and additional radiographic imaging tailored to clinical manifestations. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Empiric antibiotic therapy
         </strong>
         – While awaiting blood culture results, the decision to start or withhold antibiotic therapy must be individualized. For patients with hemodynamic instability and clinical presentation suggestive of IE, we suggest administration of empiric antibiotic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who are clinically stable, antimicrobial therapy may be deferred while awaiting the results of blood cultures and other diagnostic tests. (See
         <a class="local">
          'Empiric antibiotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgical assessment
         </strong>
         – Surgical consultation is warranted for all patients with IE. Indications for surgery in right-sided IE include very large vegetations, recurrent septic pulmonary emboli, presence of a highly resistant organism, and/or persistent bacteremia. (See
         <a class="local">
          'Surgical assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Targeted antibiotic therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Uncomplicated right-sided NVE due to MSSA
         </strong>
         – For patients with uncomplicated native valve right-sided IE due to methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA), we recommend treatment with a beta-lactam antibiotic (in preference to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Regimens include
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         , or flucloxacillin; the duration of therapy is two weeks. For patients with hypersensitivity to the preceding agents, a two-week regimen of
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         may be given; however, this agent is not as well studied for treatment of right-sided IE as the semisynthetic penicillins. We recommend NOT administering adjunctive aminoglycosides for treatment of right-sided IE due to MSSA (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Uncomplicated right-sided NVE due to MSSA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Targeted therapy for other patients
         </strong>
         – For patients with complicated right-sided IE due to MSSA or right-sided IE due to methicillin-resistant
         <em>
          S. aureus
         </em>
         or other pathogens, treatment is as for left-sided IE. Such patients include those with concomitant left-sided IE, presence of cardiac complications (such as paravalvular abscess, heart block), metastatic infection, failure to defervesce within 48 to 72 hours of appropriate antibiotic therapy, and renal failure. (See
         <a class="local">
          'Targeted therapy for other patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2102755586">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Daniel J Sexton, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-Sided Infective Endocarditis and Pulmonary Infiltrates: An Update. Cardiol Rev 2016; 24:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akinosoglou K, Apostolakis E, Marangos M, Pasvol G. Native valve right sided infective endocarditis. Eur J Intern Med 2013; 24:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HUSSEY HH, KATZ S. Infections resulting from narcotic addiction; report of 102 cases. Am J Med 1950; 9:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smit J, Korup E, Schønheyder HC. Infections associated with permanent pacemakers and implanted cardioverter-defibrillator devices. A 10-year regional study in Denmark. Scand J Infect Dis 2010; 42:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uslan DZ, Sohail MR, St Sauver JL, et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med 2007; 167:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreillon P, Que YA. Infective endocarditis. Lancet 2004; 363:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naidoo DP. Right-sided endocarditis in the non-drug addict. Postgrad Med J 1993; 69:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revilla A, López J, Villacorta E, et al. Isolated right-sided valvular endocarditis in non-intravenous drug users. Rev Esp Cardiol 2008; 61:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlin JA, Abrutyn E, Strom BL, et al. Incidence of infective endocarditis in the Delaware Valley, 1988-1990. Am J Cardiol 1995; 76:933.
          </a>
         </li>
         <li class="breakAll">
          Weinstein WL, Brusch JL. Infective endocarditis, Oxford University Press, New York City 1996.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wurcel AG, Anderson JE, Chui KK, et al. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis 2016; 3:ofw157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schranz AJ, Fleischauer A, Chu VH, et al. Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data. Ann Intern Med 2019; 170:31.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Substance Abuse and Mental Health Services Administration, Rockville, MD 2014. https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf (Accessed on May 16, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudasill SE, Sanaiha Y, Mardock AL, et al. Clinical Outcomes of Infective Endocarditis in Injection Drug Users. J Am Coll Cardiol 2019; 73:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence - North Carolina, 2010-2015. MMWR Morb Mortal Wkly Rep 2017; 66:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhandari R, Alexander T, Annie FH, et al. Steep rise in drug use-associated infective endocarditis in West Virginia: Characteristics and healthcare utilization. PLoS One 2022; 17:e0271510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meisner JA, Anesi J, Chen X, Grande D. Changes in Infective Endocarditis Admissions in Pennsylvania During the Opioid Epidemic. Clin Infect Dis 2020; 71:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geirsson A, Schranz A, Jawitz O, et al. The Evolving Burden of Drug Use Associated Infective Endocarditis in the United States. Ann Thorac Surg 2020; 110:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spijkerman IJ, van Ameijden EJ, Mientjes GH, et al. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol 1996; 49:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manoff SB, Vlahov D, Herskowitz A, et al. Human immunodeficiency virus infection and infective endocarditis among injecting drug users. Epidemiology 1996; 7:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson LE, Thomas DL, Astemborski J, et al. Prospective study of infective endocarditis among injection drug users. J Infect Dis 2002; 185:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellicelli AM, Pino P, Terranova A, et al. Eustachian valve endocarditis: a rare localization of right side endocarditis. A case report and review of the literature. Cardiovasc Ultrasound 2005; 3:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zijlstra F, Fioretti P, Roelandt JR. Echocardiographic demonstration of free wall vegetative endocarditis complicated by a pulmonary embolism in a patient with ventricular septal defect. Br Heart J 1986; 55:497.
          </a>
         </li>
         <li class="breakAll">
          Sande MA, Lee BL, Mills J, et al. Endocarditis in intravenous drug users. In: Infective Endocarditis, Kaye D (Ed), Raven Press, New York City 1992. p.345.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew J, Addai T, Anand A, et al. Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 1995; 155:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pons-Lladó G, Carreras F, Borrás X, et al. Findings on Doppler echocardiography in asymptomatic intravenous heroin users. Am J Cardiol 1992; 69:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuazon CU, Sheagren JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974; 129:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis 2000; 30:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers HF, Morris DL, Täuber MG, Modin G. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987; 106:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiNubile MJ. Abbreviated therapy for right-sided Staphylococcus aureus endocarditis in injecting drug users: the time has come? Eur J Clin Microbiol Infect Dis 1994; 13:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med 1992; 117:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortiz-Bautista C, López J, García-Granja PE, et al. Current profile of infective endocarditis in intravenous drug users: The prognostic relevance of the valves involved. Int J Cardiol 2015; 187:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine DP, Crane LR, Zervos MJ. Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis 1986; 8:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodger L, Glockler-Lauf SD, Shojaei E, et al. Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs. JAMA Netw Open 2018; 1:e185220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miró JM, Puig de la Bellacasa J, Odds FC, et al. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis 1987; 156:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shekar R, Rice TW, Zierdt CH, Kallick CA. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. J Infect Dis 1985; 151:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saydain G, Singh J, Dalal B, et al. Outcome of patients with injection drug use-associated endocarditis admitted to an intensive care unit. J Crit Care 2010; 25:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy NL, Baggs J, See I, et al. Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012-2017. Clin Infect Dis 2020; 71:e37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raoult D, Casalta JP, Richet H, et al. Contribution of systematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol 2005; 43:5238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan SM. Right-sided infective endocarditis: recent epidemiologic changes. Int J Clin Exp Med 2014; 7:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguado JM, Arjona R, Ugarte P. Septic pulmonary emboli. A rare cause of bilateral pneumothorax in drug abusers. Chest 1990; 98:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller KA, Zürn CS, Patrik H, et al. Massive haemoptysis in an intravenous drug user with infective tricuspid valve endocarditis. BMJ Case Rep 2010; 2010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palepu A, Cheung SS, Montessori V, et al. Factors other than the Duke criteria associated with infective endocarditis among injection drug users. Clin Invest Med 2002; 25:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. Clin Infect Dis 2023; 77:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prendergast BD. Diagnostic criteria and problems in infective endocarditis. Heart 2004; 90:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colen TW, Gunn M, Cook E, Dubinsky T. Radiologic manifestations of extra-cardiac complications of infective endocarditis. Eur Radiol 2008; 18:2433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mularoni A, Mikulska M, Barbera F, et al. Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diagnosis and Targeted Therapy of Infective Endocarditis: A Prospective Study. Clin Infect Dis 2023; 76:e1484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San Román JA, Vilacosta I. Role of transesophageal echocardiography in right-sided endocarditis. Echocardiography 1995; 12:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San Román JA, Vilacosta I, López J, et al. Role of transthoracic and transesophageal echocardiography in right-sided endocarditis: one echocardiographic modality does not fit all. J Am Soc Echocardiogr 2012; 25:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San Román JA, Vilacosta I, Zamorano JL, et al. Transesophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol 1993; 21:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín-Dávila P, Navas E, Fortún J, et al. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size. Am Heart J 2005; 150:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain ST, Witten J, Shrestha NK, et al. Tricuspid valve endocarditis. Ann Cardiothorac Surg 2017; 6:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanagawa B, Elbatarny M, Verma S, et al. Surgical Management of Tricuspid Valve Infective Endocarditis: A Systematic Review and Meta-Analysis. Ann Thorac Surg 2018; 106:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortún J, Navas E, Martínez-Beltrán J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med 1994; 121:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortún J, Pérez-Molina JA, Añón MT, et al. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother 1995; 39:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tissot-Dupont H, Gouriet F, Oliver L, et al. High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis. Int J Antimicrob Agents 2019; 54:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demonchy E, Dellamonica P, Roger PM, et al. Audit of antibiotic therapy used in 66 cases of endocarditis. Med Mal Infect 2011; 41:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mzabi A, Kernéis S, Richaud C, et al. Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients. Clin Microbiol Infect 2016; 22:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki J, Johnson J, Montgomery M, et al. Outpatient Parenteral Antimicrobial Therapy Among People Who Inject Drugs: A Review of the Literature. Open Forum Infect Dis 2018; 5:ofy194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price CN, Solomon DA, Johnson JA, et al. Feasibility and Safety of Outpatient Parenteral Antimicrobial Therapy in Conjunction With Addiction Treatment for People Who Inject Drugs. J Infect Dis 2020; 222:S494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019; 68:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Weimer MB, Wurcel AG, et al. Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association. Circulation 2022; 146:e187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs. Clin Infect Dis 2023; 76:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alagna L, Park L, Nicholson B, et al. Repeat endocarditis – a consequence of medical progress? Analysis of risk factors based on International Collaboration on Endocarditis – Prospective Cohort Study (ICE-PCS). Clin Microbiol Infect 2012; 18:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang G, Barnes EW, Peacock JE Jr. Repeat Infective Endocarditis in Persons Who Inject Drugs: "Take Another Little Piece of my Heart". Open Forum Infect Dis 2018; 5:ofy304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu VH, Sexton DJ, Cabell CH, et al. Repeat infective endocarditis: differentiating relapse from reinfection. Clin Infect Dis 2005; 41:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew J, Abreo G, Namburi K, et al. Results of surgical treatment for infective endocarditis in intravenous drug users. Chest 1995; 108:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayer AS, Blomquist IK, Bello E, et al. Tricuspid valve endocarditis due to Staphylococcus aureus. Correlation of two-dimensional echocardiography with clinical outcome. Chest 1988; 93:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribera E, Miró JM, Cortés E, et al. Influence of human immunodeficiency virus 1 infection and degree of immunosuppression in the clinical characteristics and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 1998; 158:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemaire A, Dombrovskiy V, Saadat S, et al. Patients with Infectious Endocarditis and Drug Dependence Have Worse Clinical Outcomes after Valvular Surgery. Surg Infect (Larchmt) 2017; 18:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabkin DG, Mokadam NA, Miller DW, et al. Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users. Ann Thorac Surg 2012; 93:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thalme A, Westling K, Julander I. In-hospital and long-term mortality in infective endocarditis in injecting drug users compared to non-drug users: a retrospective study of 192 episodes. Scand J Infect Dis 2007; 39:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JB, Ejiofor JI, Yammine M, et al. Surgical outcomes of infective endocarditis among intravenous drug users. J Thorac Cardiovasc Surg 2016; 152:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrestha NK, Jue J, Hussain ST, et al. Injection Drug Use and Outcomes After Surgical Intervention for Infective Endocarditis. Ann Thorac Surg 2015; 100:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østerdal OB, Salminen PR, Jordal S, et al. Cardiac surgery for infective endocarditis in patients with intravenous drug use. Interact Cardiovasc Thorac Surg 2016; 22:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori M, Bin Mahmood SU, Schranz AJ, et al. Risk of reoperative valve surgery for endocarditis associated with drug use. J Thorac Cardiovasc Surg 2020; 159:1262.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2149 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26501991" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Right-Sided Infective Endocarditis and Pulmonary Infiltrates: An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23369408" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Native valve right sided infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15432465" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Infections resulting from narcotic addiction; report of 102 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20465488" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Infections associated with permanent pacemakers and implanted cardioverter-defibrillator devices. A 10-year regional study in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17420425" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726169" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8234104" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Right-sided endocarditis in the non-drug addict.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19080963" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Isolated right-sided valvular endocarditis in non-intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7484834" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Incidence of infective endocarditis in the Delaware Valley, 1988-1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7484834" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence of infective endocarditis in the Delaware Valley, 1988-1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27800528" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30508432" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30508432" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30732709" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical Outcomes of Infective Endocarditis in Injection Drug Users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28594786" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence - North Carolina, 2010-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35839224" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Steep rise in drug use-associated infective endocarditis in West Virginia: Characteristics and healthcare utilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630192" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Changes in Infective Endocarditis Admissions in Pennsylvania During the Opioid Epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32387035" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Evolving Burden of Drug Use Associated Infective Endocarditis in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8826995" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8899380" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Human immunodeficiency virus infection and infective endocarditis among injecting drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085322" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prospective study of infective endocarditis among injection drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16171516" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Eustachian valve endocarditis: a rare localization of right side endocarditis. A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3707790" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Echocardiographic demonstration of free wall vegetative endocarditis complicated by a pulmonary embolism in a patient with ventricular septal defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3707790" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Echocardiographic demonstration of free wall vegetative endocarditis complicated by a pulmonary embolism in a patient with ventricular septal defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7618988" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1731465" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Findings on Doppler echocardiography in asymptomatic intravenous heroin users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4834284" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Increased rate of carriage of Staphylococcus aureus among narcotic addicts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10671344" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3579070" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cocaine use and the risk for endocarditis in intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7805679" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Abbreviated therapy for right-sided Staphylococcus aureus endocarditis in injecting drug users: the time has come?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1524330" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25846656" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Current profile of infective endocarditis in intravenous drug users: The prognostic relevance of the valves involved.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3755255" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646383" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1457662" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3309077" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Systemic candidiasis in Spanish heroin addicts: a possible source of infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3918121" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906509" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Outcome of patients with injection drug use-associated endocarditis admitted to an intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31907515" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16207989" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Contribution of systematic serological testing in diagnosis of infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20048212" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24482708" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Right-sided infective endocarditis: recent epidemiologic changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2225993" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Septic pulmonary emboli. A rare cause of bilateral pneumothorax in drug abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22767369" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Massive haemoptysis in an intravenous drug user with infective tricuspid valve endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12220038" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Factors other than the Duke criteria associated with infective endocarditis among injection drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37138445" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15145855" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Diagnostic criteria and problems in infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18523779" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Radiologic manifestations of extra-cardiac complications of infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35686318" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diagnosis and Targeted Therapy of Infective Endocarditis: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10158104" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Role of transesophageal echocardiography in right-sided endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22727494" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Role of transthoracic and transesophageal echocardiography in right-sided endocarditis: one echocardiographic modality does not fit all.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8459081" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Transesophageal echocardiography in right-sided endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291005" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28706868" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Tricuspid valve endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29750928" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Surgical Management of Tricuspid Valve Infective Endocarditis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3421575" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8967707" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11389505" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7978701" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19207079" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7726526" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16914701" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31181351" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21924571" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Audit of antibiotic therapy used in 66 cases of endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27091094" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30211247" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Outpatient Parenteral Antimicrobial Therapy Among People Who Inject Drugs: A Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32877541" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Feasibility and Safety of Outpatient Parenteral Antimicrobial Therapy in Conjunction With Addiction Treatment for People Who Inject Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423035" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36043414" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36052413" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Repeat endocarditis–a consequence of medical progress? Analysis of risk factors based on International Collaboration on Endocarditis–Prospective Cohort Study (ICE-PCS)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30555849" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Repeat Infective Endocarditis in Persons Who Inject Drugs: "Take Another Little Piece of my Heart".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16007540" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Repeat infective endocarditis: differentiating relapse from reinfection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7606996" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Results of surgical treatment for infective endocarditis in intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3338291" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Tricuspid valve endocarditis due to Staphylococcus aureus. Correlation of two-dimensional echocardiography with clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778205" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Influence of human immunodeficiency virus 1 infection and degree of immunosuppression in the clinical characteristics and outcome of infective endocarditis in intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28099093" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Patients with Infectious Endocarditis and Drug Dependence Have Worse Clinical Outcomes after Valvular Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22054655" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17366047" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : In-hospital and long-term mortality in infective endocarditis in injecting drug users compared to non-drug users: a retrospective study of 192 episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27068439" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Surgical outcomes of infective endocarditis among intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26095108" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Injection Drug Use and Outcomes After Surgical Intervention for Infective Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26826713" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Cardiac surgery for infective endocarditis in patients with intravenous drug use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31420136" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Risk of reoperative valve surgery for endocarditis associated with drug use.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
